159 related articles for article (PubMed ID: 23731285)
21. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
22. Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
Pochechueva T; Chinarev A; Schoetzau A; Fedier A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V
PLoS One; 2016; 11(10):e0164230. PubMed ID: 27764122
[TBL] [Abstract][Full Text] [Related]
23. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
Zou L; He X; Zhang JW
Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
[TBL] [Abstract][Full Text] [Related]
25. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
26. A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.
Gidwani K; Huhtinen K; Kekki H; van Vliet S; Hynninen J; Koivuviita N; Perheentupa A; Poutanen M; Auranen A; Grenman S; Lamminmäki U; Carpen O; van Kooyk Y; Pettersson K
Clin Chem; 2016 Oct; 62(10):1390-400. PubMed ID: 27540033
[TBL] [Abstract][Full Text] [Related]
27. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
Zhang Z; Bast RC; Yu Y; Li J; Sokoll LJ; Rai AJ; Rosenzweig JM; Cameron B; Wang YY; Meng XY; Berchuck A; Van Haaften-Day C; Hacker NF; de Bruijn HW; van der Zee AG; Jacobs IJ; Fung ET; Chan DW
Cancer Res; 2004 Aug; 64(16):5882-90. PubMed ID: 15313933
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
29. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of serum mesothelin in malignant and benign ovarian masses.
Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
[TBL] [Abstract][Full Text] [Related]
31. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
[TBL] [Abstract][Full Text] [Related]
32. Glycoproteomic identification of novel plasma biomarkers for oral cancer.
Chang SC; Lin WL; Chang YF; Lee CT; Wu JS; Hsu PH; Chang CF
J Food Drug Anal; 2019 Apr; 27(2):483-493. PubMed ID: 30987719
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of differential plasma proteins levels in epithelial ovarian cancer.
Periyasamy A; Gopisetty G; Subramanium MJ; Velusamy S; Rajkumar T
J Proteomics; 2020 Aug; 226():103893. PubMed ID: 32634479
[TBL] [Abstract][Full Text] [Related]
34. Early detection and prognosis of ovarian cancer using serum YKL-40.
Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of long noncoding RNA-taurine-upregulated gene 1 inhibits tumor angiogenesis in ovarian cancer by regulating leucine-rich α-2-glycoprotein-1.
Fan M; Li C; He P; Fu Y; Li M; Zhao X
Anticancer Drugs; 2019 Jul; 30(6):562-570. PubMed ID: 30896502
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
[TBL] [Abstract][Full Text] [Related]
37. Nidogen-1: a candidate biomarker for ovarian serous cancer.
Li L; Zhang Y; Li N; Feng L; Yao H; Zhang R; Li B; Li X; Han N; Gao Y; Xiao T; Wu L
Jpn J Clin Oncol; 2015 Feb; 45(2):176-82. PubMed ID: 25378651
[TBL] [Abstract][Full Text] [Related]
38. Glycomics analysis of serum: a potential new biomarker for ovarian cancer?
Leiserowitz GS; Lebrilla C; Miyamoto S; An HJ; Duong H; Kirmiz C; Li B; Liu H; Lam KS
Int J Gynecol Cancer; 2008; 18(3):470-5. PubMed ID: 17655680
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
40. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
Zheng H; Gao Y
Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
